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Background
OnabotulinumtoxinA (Botox®) is the first and so far the
only treatment to receive a specific license for preven-
tion of chronic migraine (CM). In our Headache Clinic
the therapy with onabotulinumtoxinA is routinely admi-
nistered to CM patients on a daily basis since 2001.
Preventive treatment with onabotulinumtoxinA was
offered to all patients that were 1) adults; 2) fulfilling
the ICHD-II criteria for CM with or without analgesic
overuse; and 3) with contraindications or lack of efficacy
or tolerability to other preventive drugs.
Exclusion criteria were coexistent neuromuscular dis-
orders, psychiatric diseases considered incompatible with
this kind of treatment, pregnancy and breast-feeding.
Objectives
To prospectively evaluate the variations in terms of
headache days, migraine days, acute pain medication
intake days through a period of 24 months in compari-
son to a one-month baseline period before starting the
therapy.
Methods
Among all the patients that from 2011 to 2012 under-
went treatment with onabotulinumtoxinA we randomly
selected 100 CM patients (F 88 / M 12; mean age 43.2,
range 18-80 years; 96% drugs overusers) that were able to
fill in diaries without any lack of information for a period
of 2 years. OnabotulinumtoxinA 155 U was injected in
31 sites following the PREEMPT “fixed sites/fixed doses”
injection paradigm every three months (± one week) [1].
Patients with criteria for medication-overuse headache
underwent withdrawal and detoxification therapeutic
regimen before starting the treatment. Patients were not
allowed to continue preventive oral medication during
treatment with onabotulinumtoxinA.
Results
The efficacy results for each timeline are reported in Table
1. The reduction in terms of headache and migraine days,
acute medication intake days and HIT-6 score increases
strongly from the first injection to the fourth, and remains
stable until the last injection at 24 months.
Conclusions
Our results support findings of PREEMPT study in a
large cohort of patients and are representative of the
patients observed in a tertiary headache centre.
Written informed consent to publish was obtained
from the patient(s).
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Table 1. Efficacy of onabotulinumtoxinA 155 U
baseline 3 m 6 m 9 m 12 m 15 m 18 m 21 m 24 m
Headache days 22.3 -5.9 -9.4 -10.7 -12.9 -13.2 -13.6 -14.3 -15
Migraine days 21.4 -5.6 -8.4 -9.5 -12.3 -13.1 -13.5 -14.1 -14.6
Acute pain medication intake days 20.8 -6.6 -9 -9.8 -12.1 -12.6 -13.2 -14.8 -15.6
HIT-6 score 69.4 – -5.1 – -10.9 – -14 – -17.4
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